Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Chemoradiation in Node-positive Esophageal Squamous Cell Carcinoma
NCT02446574Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2007
- Primary completion
- Dec 2016
- Countries
- 1
- Sponsor
- Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Drugs
- paclitaxel
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Maximum Tolerated Dose at 3 months. Started Jul 2007; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Arm A
Paclitaxel + Cisplatin + Radiation
03
Endpoints
Primary
Maximum Tolerated Dose
Secondary
Toxicities
Overall Survival
Disease-Free Survival
Beyond the preview
Go deeper on NCT02446574.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446574.